IPM Take
MASH is still too often treated as a liver problem. That is already outdated. Patients with MASH frequently carry a wider cardiometabolic burden, including obesity, insulin resistance, dyslipidaemia, hypertension and elevated cardiovascular risk. The EASL 2026 pemvidutide data are important because they point toward a future where MASH therapies may be judged across multiple systems, not just the liver. The policy question is whether payers and health systems are ready for that. If reimbursement focuses only on liver histology while clinical risk is spread across heart, kidney and metabolic pathways, access decisions will miss the real disease.
Executive Summary
At EASL Congress 2026 in Barcelona, Altimmune presented new 48-week data from the Phase 2b IMPACT trial of pemvidutide in patients with metabolic dysfunction-associated steatohepatitis, or MASH. Pemvidutide is an investigational balanced glucagon/GLP-1 dual receptor agonist being developed for serious liver diseases. The IMPACT trial enrolled 212 participants with biopsy-confirmed MASH and fibrosis stages F2 or F3, with and without diabetes. New analyses presented at EASL showed improvements in several cardiometabolic risk factors among patients receiving pemvidutide 1.8 mg, including reductions in triglycerides, total cholesterol, body weight, BMI, waist circumference and blood pressure. Previously reported findings also showed improvements in non-invasive liver fibrosis markers. The signal is clear: MASH drug development is moving toward multi-system metabolic benefit, but care pathways and reimbursement models remain fragmented.
Why it matters
- Clinicians: MASH management increasingly requires coordination between hepatology, endocrinology, cardiology, obesity medicine and primary care.
- HTA bodies: Future value assessments may need to consider cardiometabolic outcomes alongside liver-related endpoints, especially where cardiovascular disease drives patient risk.
- Payers: Reimbursement decisions will need to decide whether therapies are funded as liver drugs, metabolic drugs, obesity drugs or multi-system cardiometabolic interventions.
- Patients: People with MASH may benefit from treatments that address liver disease and broader metabolic risk, but access may depend on diagnosis and specialist referral.
- Industry / innovation partners: The competitive field is shifting toward therapies that can show liver, weight, lipid and cardiovascular-risk signals together.
MASH has a branding problem. It sounds like a liver disease. It is a liver disease.
But treating it only as a liver disease is becoming clinically and politically absurd.
Metabolic dysfunction-associated steatohepatitis, or MASH, sits inside a wider cardiometabolic crisis. Many patients also live with obesity, type 2 diabetes, insulin resistance, hypertension, dyslipidaemia or elevated cardiovascular risk. For many, the liver is not an isolated organ failure story. It is one visible expression of a system-wide metabolic breakdown.
That is why new data presented at EASL Congress 2026 matter.
At the Barcelona meeting, Altimmune presented new 48-week findings from the Phase 2b IMPACT trial of pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, in patients with biopsy-confirmed MASH.
The trial enrolled 212 participants with MASH and fibrosis stages F2 or F3, with and without diabetes. Participants were randomised to weekly subcutaneous pemvidutide 1.2 mg, pemvidutide 1.8 mg or placebo for 48 weeks.
The new EASL data focused on metabolic improvements.
Among patients with elevated baseline lipid levels, pemvidutide 1.8 mg was associated with triglyceride reductions of 23.7% and total cholesterol reductions of 15.4% versus placebo. The same dose was also associated with 7.5% weight loss, a 3.0 kg/m² reduction in BMI, a 5.3 cm reduction in waist circumference and blood pressure improvements of 4.0 mmHg systolic and 2.2 mmHg diastolic.
Those numbers are not just cosmetic.
In MASH, cardiometabolic risk is central to the disease. Visceral adiposity, insulin resistance, lipid abnormalities and blood pressure all contribute to long-term outcomes. Cardiovascular disease remains a major cause of death in this population. That means a MASH therapy that improves liver markers but ignores metabolic risk would only solve part of the problem.
Pemvidutide is interesting because it is being positioned as more than a liver-targeted therapy.
Its mechanism combines glucagon and GLP-1 receptor activity. The GLP-1 component is familiar from diabetes and obesity care. The glucagon component is intended to increase energy expenditure and may contribute to liver fat reduction and broader metabolic effects. The result is a drug development strategy that does not treat MASH as a single-organ problem.
That is the personalised medicine angle.
MASH is not one clean disease. Patients differ by fibrosis stage, diabetes status, obesity phenotype, lipid profile, cardiovascular risk, kidney function and inflammatory burden. Some may need weight-centred treatment. Others may need liver-fibrosis targeting. Others may need aggressive cardiometabolic risk reduction. The future pathway will not be one-size-fits-all.
But the health system is still built that way.
A patient with MASH may be detected through abnormal liver enzymes in primary care, assessed by hepatology, managed for diabetes by endocrinology, treated for hypertension by primary care or cardiology, and judged for drug reimbursement through a liver-specific HTA framework. The patient is integrated. The system is not.
That mismatch is the policy problem.
If MASH therapies advance, payers will face difficult questions. Should access depend on biopsy-confirmed fibrosis stage? Non-invasive fibrosis tests? Diabetes status? BMI? Cardiovascular risk? Prior failure of lifestyle intervention? Specialist hepatology referral?
Each answer will create winners and losers.
If eligibility is too narrow, patients with high cardiometabolic risk may be excluded until liver disease progresses. If eligibility is too broad, budgets may come under pressure before long-term outcome evidence is mature. If testing pathways are weak, only patients who reach specialist centres will be diagnosed and treated.
That is where diagnostics become political.
MASH has long suffered from underdiagnosis because patients may be asymptomatic for years. Non-invasive tests such as FIB-4, elastography, ELF and imaging-based approaches are increasingly important, but their use remains uneven. Without structured case-finding, new therapies will not reach the patients who need them. They will reach the patients who happen to pass through the right pathway.
For industry, the message from EASL 2026 is also clear.
The MASH field is moving toward multi-endpoint competition. It will not be enough to show a liver signal in isolation. The strongest value stories will likely combine fibrosis, liver fat, weight, lipids, blood pressure, glycaemia, safety and eventually hard outcomes.
For HTA bodies, that creates a challenge.
Traditional assessment frameworks like clean categories: liver drug, diabetes drug, obesity drug, cardiovascular prevention drug. MASH does not respect those categories. The benefit may be distributed across liver, heart and metabolic risk. If assessment is too siloed, value may be underestimated.
The lesson is simple.
MASH is not waiting for health systems to reorganise.
The science is already moving into multi-system cardiometabolic treatment.
The question is whether reimbursement, diagnostics and care pathways will move with it.
Because if MASH is treated only when the liver is already damaged, the system has already failed.
